Brain Cancer Clinical Trials in Maryland

Showing 81-100 of 268 trials

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

NCT01734512

This is an open label study of everolimus in children with recurrent or progressive low-grade glioma.

Pediatric Recurrent Progressive Low-grade GliomasPediatric Progressive Low-grade Gliomas

University of California, San Francisco65 participantsStarted Dec 2012

Los Angeles, California, United States • Los Angeles, California, United States • Oakland, California, United States +15 more locations

Approved For Marketing17 miles

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

NCT04617002

This is an intermediate-size expanded access protocol to provide ONC201 (dordaviprone) to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 (dordaviprone) through clinical trials.

GliomaH3 K27M

Jazz Pharmaceuticals

Phoenix, Arizona, United States • Los Angeles, California, United States • Orange, California, United States +20 more locations

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Brain Cancer Trials in Other Cities

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM

Safety and Effectiveness of Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma

A Study of Abemaciclib in Recurrent Glioblastoma

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

9-ING-41 in Pediatric Patients With Refractory Malignancies.

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma

A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102

VB-111 in Surgically Accessible Recurrent/Progressive GBM

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma

Other Conditions in Maryland